Ro 27-2771

Ro 27-2771 is an investigational small molecule dual integrin antagonist developed by Hoffmann-La Roche for the treatment of persistent asthma. It functions by blocking the $\alpha_4\beta_1$ (also known as Very Late Antigen-4 or VLA-4) and $\alpha_4\beta_7$ integrins, which are critical for the adhesion and transendothelial migration of inflammatory cells, such as eosinophils and T-lymphocytes, into airway tissues. By inhibiting the interaction of these integrins with their respective ligands, vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), the drug aims to attenuate the chronic airway inflammation characteristic of asthma. Ro 27-2771 was primarily evaluated in clinical development as its oral prodrug form, Ro 27-2441. A Phase 2 dose-ranging study was conducted to assess its efficacy and safety in patients with persistent asthma who were not receiving inhaled corticosteroids, but the development program was subsequently discontinued.

Other names

valategrast hydrochlorideR 411 (pharmaceutical)